Get the Stockscreener App
9.35
12.79%
1.06
Pre-market:
8.00
-1.35
-14.44%
Aardvark Therapeutics Inc stock is traded at $9.35, with a volume of 99,685.
It is up +12.79% in the last 24 hours and down -26.55% over the past month.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
See More
Previous Close:
$8.29
Open:
$8.39
24h Volume:
99,685
Relative Volume:
1.46
Market Cap:
$199.94M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.74%
1M Performance:
-26.55%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$8.01
$9.42
1-Week Range:
$6.79
$10.38
52-Week Range:
$6.79
$19.58
Aardvark Therapeutics Inc Stock (AARD) Company Profile
Name
Aardvark Therapeutics Inc
Sector
Industry
Phone
(858) 225-7696
Address
4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO
Compare AARD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AARD
Aardvark Therapeutics Inc
|
9.35 | 199.94M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-25 | Initiated | BofA Securities | Buy |
| Mar-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-10-25 | Initiated | Morgan Stanley | Overweight |
| Mar-10-25 | Initiated | RBC Capital Mkts | Outperform |
Aardvark Therapeutics Inc Stock (AARD) Latest News
Aardvark Therapeutics (NASDAQ:AARD) Receives “Overweight” Rating from Cantor Fitzgerald - Defense World
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock By Investing.com - Investing.com Australia
RBC Capital maintains $21 target on Aardvark Therapeutics stock - Investing.com
Cantor Fitzgerald maintains $50 target on Aardvark Therapeutics stock - Investing.com
Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights - The Manila Times
BofA lifts Aardvark Therapeutics target to $26, maintains Buy By Investing.com - Investing.com Canada
Positive Outlook for Aardvark Therapeutics Amid Favorable Regulatory and Market Conditions - TipRanks
Aardvark Therapeutics price target raised to $26 from $22 at BofA - TipRanks
BofA lifts Aardvark Therapeutics target to $26, maintains Buy - Investing.com India
Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (NASDAQ:SLNO) - Seeking Alpha
Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month - Yahoo Finance
Top 10 Insider Purchases Last Month - Insider Monkey
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Royal Bank of Canada - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Coverage Initiated by Analysts at Bank of America - Defense World
BofA sets Aardvark Therapeutics stock with $22 target By Investing.com - Investing.com Australia
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Morgan Stanley - Defense World
Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Cantor Fitzgerald - Defense World
BofA Initiates Aardvark Therapeutics at Buy With $22 Price Target -March 10, 2025 at 10:01 am EDT - Marketscreener.com
RBC Capital sets Aardvark Therapeutics at Outperform - Investing.com
This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
RBC Capital sets Aardvark Therapeutics at Outperform By Investing.com - Investing.com South Africa
Aardvark Therapeutics initiated with an Overweight at Cantor Fitzgerald - TipRanks
Morgan Stanley Initiates Aardvark Therapeutics at Overweight -March 10, 2025 at 08:13 am EDT - Marketscreener.com
Cantor Fitzgerald Initiates Aardvark Therapeutics at Overweight With $50 Price Target -March 10, 2025 at 08:03 am EDT - Marketscreener.com
BofA sets Aardvark Therapeutics stock with $22 target - Investing.com India
RBC Initiates Aardvark Therapeutics at Outperform With $21 Price Target, Speculative Risk Qualifier - Marketscreener.com
Morgan Stanley sets Aardvark stock target at $29, rating Overweight By Investing.com - Investing.com South Africa
Morgan Stanley sets Aardvark stock target at $29, rating Overweight - Investing.com
San Diego had its first biotech IPO of 2025. Are more on the way? - MSN
Aardvark Therapeutics’ $94.2 Million Initial Public Offering - Global Legal Chronicle
Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently - Insider Monkey
IPOs Numbers Rise In 2024, But Dwindling Returns Could Diminish Potential In 2025 - Scrip
Biotechs Highlight 6 Stocks Insiders Are Buying Now - 24/7 Wall St.
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight - GlobeNewswire Inc.
Big Moves: Major Stakeholders Invest Heavily in Aardvark Therapeutics - TipRanks
Autism Spectrum Disorder Treatment Market Size is expected - openPR
Aardvark therapeutics sees $20m stock purchase by Decheng capital - Investing.com India
DAC specialist Orum raises $35M with Kosdaq IPO - BioWorld Online
Finance Watch: Investors’ Appetite For Aardvark Wanes After $94.2m IPO - News & Insights
Orum, Aardvark IPOs trade in opposite directions: Public Equity Report - biocentury.com
Aardvark stock slides 11% following $94M IPO - MSN
Aardvark stock slides 11% following $94M IPO (AARD:NASDAQ) - Seeking Alpha
Aardvark Therapeutics prices $94M IPO at $16 per share - MSN
Aardvark Lands $94M IPO as Biotech Wave Gains Momentum - USA Herald
Aardvark Therapeutics Shares Below IPO Price on Nasdaq Debut -February 13, 2025 at 12:17 pm EST - Marketscreener.com
Paul Hastings, Cooley Lead Obesity-Focused Aardvark's IPO - Law360
Aardvark Therapeutics Inc Stock (AARD) Financials Data
There is no financial data for Aardvark Therapeutics Inc (AARD). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):